Durect Corporation (DRRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Durect Corporation (DRRX) has a cash flow conversion efficiency ratio of -0.447x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.76 Million) by net assets ($3.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Durect Corporation net asset quality index to measure how much of total assets are equity-financed.
Durect Corporation - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Durect Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Durect Corporation's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Durect Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Durect Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Youngbo Chem
KO:014440
|
0.027x |
|
JAKS Resources Bhd
KLSE:4723
|
-0.007x |
|
Gold Terra Resource Corp
V:YGT
|
-0.016x |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
0.013x |
|
Ni Steel
KO:008260
|
0.075x |
|
VITA 34 AG
XETRA:V3V
|
0.078x |
|
DocGo Inc
NASDAQ:DCGO
|
-41882.840x |
|
Fortune Oriental Co Ltd
TW:2491
|
0.034x |
Annual Cash Flow Conversion Efficiency for Durect Corporation (1999–2024)
The table below shows the annual cash flow conversion efficiency of Durect Corporation from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Durect Corporation (DRRX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.13 Million | $-19.09 Million | -2.090x | +10.21% |
| 2023-12-31 | $14.78 Million | $-34.41 Million | -2.328x | -121.32% |
| 2022-12-31 | $24.98 Million | $-26.28 Million | -1.052x | -62.89% |
| 2021-12-31 | $57.78 Million | $-37.31 Million | -0.646x | +33.07% |
| 2020-12-31 | $40.12 Million | $-38.70 Million | -0.965x | -298.68% |
| 2019-12-31 | $22.86 Million | $11.10 Million | 0.486x | +149.18% |
| 2018-12-31 | $20.00 Million | $-19.75 Million | -0.988x | -1480.00% |
| 2017-12-31 | $21.49 Million | $-1.34 Million | -0.063x | +98.09% |
| 2016-12-31 | $8.34 Million | $-27.29 Million | -3.273x | -137.01% |
| 2015-12-31 | $14.88 Million | $-20.55 Million | -1.381x | -79.96% |
| 2014-12-31 | $18.52 Million | $-14.21 Million | -0.767x | -52.62% |
| 2013-12-31 | $30.72 Million | $-15.45 Million | -0.503x | -35.85% |
| 2012-12-31 | $36.33 Million | $-13.45 Million | -0.370x | +92.60% |
| 2011-12-31 | $3.48 Million | $-17.39 Million | -5.000x | -1033.13% |
| 2010-12-31 | $14.49 Million | $7.76 Million | 0.536x | +170.31% |
| 2009-12-31 | $27.42 Million | $-20.89 Million | -0.762x | -194.20% |
| 2008-12-31 | $36.42 Million | $-9.43 Million | -0.259x | +51.04% |
| 2007-12-31 | $34.58 Million | $-18.30 Million | -0.529x | -106.69% |
| 2006-12-31 | $37.03 Million | $-9.48 Million | -0.256x | -53.89% |
| 2005-12-31 | $43.35 Million | $-7.21 Million | -0.166x | +86.23% |
| 2004-12-31 | $18.39 Million | $-22.21 Million | -1.208x | -183.08% |
| 2003-12-31 | $45.12 Million | $-19.25 Million | -0.427x | +9.82% |
| 2002-12-31 | $66.18 Million | $-31.31 Million | -0.473x | -104.69% |
| 2001-12-31 | $97.05 Million | $-22.43 Million | -0.231x | -78.92% |
| 2000-12-31 | $115.25 Million | $-14.89 Million | -0.129x | +63.18% |
| 1999-12-31 | $20.73 Million | $-7.27 Million | -0.351x | -- |
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more